Yu Jiarui, Chen Siyuan, Niu Yi, Liu Meiyue, Zhang Jie, Yang Zhao, Gao Peng, Wang Wei, Han Xiaochen, Sun Guogui
School of Clinical Medicine, Affiliated Hospital, School of Public Health, North China University of Science and Technology, Tangshan, Hebei 063210, China; Department of Radiation Oncology, North China University of Science and Technology Affiliated People's Hospital, Tangshan 063000, China.
Department of Radiation Oncology, North China University of Science and Technology Affiliated People's Hospital, Tangshan 063000, China.
Mol Ther Nucleic Acids. 2020 Sep 4;21:315-331. doi: 10.1016/j.omtn.2020.05.015. Epub 2020 Jun 12.
Novel therapies tailored to the molecular composition mechanism of esophageal squamous cell carcinoma (ESCC) are needed to improve patient survival. miR-20b-5p expression was significantly upregulated in cancerous tissues and associated with lymph node metastasis, clinical stage, and overall survival (OS). An analysis of the methylation status of the miR-20b-5p gene indicated that the hypomethylation of the CpG sites located upstream of the miR-20b-5p gene in the ESCC tissues was more frequent than in the adjacent normal tissues, and the methylation status of miR-20b-5p correlated inversely with its expression levels. Notably, a series of gain- and loss-of-function assays elucidated that miR-20b-5p promoted ESCC cell proliferation, migration, and invasion both in vitro and in vivo. Luciferase reporter assays, western blot, and qRT-PCR revealed that RB1 and TP53INP1 were the direct targets of miR-20b-5p. Moreover, the effects of ectopic miR-20b-5p expression were abrogated by RB1 and TP53INP1 overexpression. In contrast, the effects of miR-20b-5p depletion were impaired by RB1 and TP53INP1 knockdown. Treatment with a miR-20b-5p antagomir dramatically increased tumor growth and inhibited RB1 and TP53INP1 protein expression in nude mice. This work provided novel insights on the molecular mechanism of ESCC and further provided suggestions for therapy development.
需要针对食管鳞状细胞癌(ESCC)分子组成机制定制新型疗法,以提高患者生存率。miR-20b-5p在癌组织中表达显著上调,且与淋巴结转移、临床分期及总生存期(OS)相关。对miR-20b-5p基因甲基化状态的分析表明,ESCC组织中miR-20b-5p基因上游CpG位点的低甲基化比相邻正常组织更常见,且miR-20b-5p的甲基化状态与其表达水平呈负相关。值得注意的是,一系列功能获得和功能丧失实验表明,miR-20b-5p在体外和体内均促进ESCC细胞增殖、迁移和侵袭。荧光素酶报告基因实验、蛋白质印迹法和qRT-PCR显示,RB1和TP53INP1是miR-20b-5p的直接靶点。此外,RB1和TP53INP1的过表达消除了异位miR-20b-5p表达的影响。相反,RB1和TP53INP1的敲低削弱了miR-20b-5p缺失的影响。用miR-20b-5p拮抗剂治疗可显著增加裸鼠肿瘤生长并抑制RB1和TP53INP1蛋白表达。这项工作为ESCC的分子机制提供了新见解,并进一步为治疗开发提供了建议。